PERLEGEN SCIENCES TO COLLABORATE ON PHARMACOGENOMICS STUDY WITH JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT

Perlegen Sciences will commence a pharmacogenomics collaboration with Johnson & Johnson Pharmaceutical Research and Development (J&JPRD), a Johnson & Johnson company. The goal of the collaboration is to identify genetic markers for patient response to a therapeutic agent in the J&JPRD portfolio. Terms of the collaboration were not disclosed. In the study, Perlegen will individually genotype single nucleotide polymorphisms, or SNPs, in hundreds of patients, analyze the results to determine the genetic variations associated with differential therapeutic response, and determine the populations that might respond best to this agent.

Yahoo News (http://biz.yahoo.com/bw/050111/115343_1.html)